Takeda oncology vet drills down the 'basics' at cell therapy startup; Sarepta promotes new R&D chief
Kathryn Corzo — an oncology veteran and the program head behind Sanofi’s multiple myeloma monoclonal antibody isatuximab — is now in the C-suite.
The newest member at cell therapy player bit.bio as their COO, the longtime drug developer left Takeda (where she served, in turn, as the head of oncology cell therapy and then a partner in its venture arm) to join the small biotech. For Corzo, bit.bio presented a unique opportunity to try and solve issues that had been plaguing cell therapy — and one of the three reasons why she left Takeda.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
